Sitavig registered in seven European countries
BioAlliance Pharma's Sitavig (aciclovir Lauriad) has been approved for the treatment of recurrent labial herpes in the following European countries: Sweden, the UK, Spain, Italy, Denmark, Finland and Norway.
The decentralised procedure, with Sweden as Reference Member State, ended with a positive opinion for these first seven countries. Each country will now issue a national marketing authorisation in the coming weeks.
BioAlliance Pharma plans to pursue the submission of the registration dossier in other European countries as soon as the first quarter of 2013.